Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report.
International Journal of Molecular Sciences（2023）
关键词
squamous cell lung cancer,lung cancer,nivolumab,ipilimumab,checkpoint inhibition therapy,abemaciclib,TMB-high
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要